Table 4 INR outcomes in the study period
IMS | MarketScan Commercial | MarketScan Medicare | Optum | Medicaid | |
|---|---|---|---|---|---|
All patients, N | 30,757 | 21,976 | 38,643 | 9,120 | 4,901 |
INR frequency of occurrence: total warfarin patient population | |||||
N (%) | 6,452/10,194 (63%) | 5,536/6,372 (87%) | 8,083/14,563 (56%) | 2,002/3,159 (63%) | 775/803 (97%) |
Average number of unique INRs per month of warfarin treatment | |||||
Unique INRs per month | 0.72 | 1.02 | 0.51 | 0.62 | 2.05 |
Monthly INR quality ratio | |||||
Quality ratio | 0.38 | 0.53 | 0.30 | 0.36 | 0.64 |